Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Albireo Pharma
Albireo Pharma
(ALBO)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Bylvay
Odevixibat
2021-07-16
2031-2041
Pruritus
,
Intrahepatic cholestasis
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Odevixibat
intrahepatic cholestasis
,
liver diseases
,
healthy volunteers/patients
,
biliary liver cirrhosis
,
liver cirrhosis
,
fibrosis
,
pruritus
,
cholestasis
,
alagille syndrome
,
syndrome
Bevifimod
allergic rhinitis seasonal
,
nasal obstruction
,
sneezing
,
dental anxiety
,
restless legs syndrome
,
spinal cord injuries
,
type 1 diabetes mellitus
,
hiv infections
,
non-small-cell lung carcinoma
,
osteoarthritis
,
breast neoplasms
,
depression
,
neurologic manifestations
,
wounds and injuries
,
central nervous system diseases
,
spinal cord diseases
,
sleep wake disorders
,
inguinal hernia
,
peripheral nervous system diseases
,
radiculopathy
,
psoriasis
,
fibromyalgia
,
healthy volunteers/patients
,
neuralgia
,
partial epilepsies
,
diabetic neuropathies
,
epilepsy
,
pain
,
sleep initiation and maintenance disorders
,
seizures
,
postherpetic neuralgia
,
postoperative pain
,
anxiety disorders
,
low back pain
,
generalized anxiety disorder
,
complex partial epilepsy
,
back pain
,
breast feeding
,
bronchiolitis obliterans syndrome
,
neoplasms
,
bone neoplasms
,
intractable pain
,
phantom limb
,
burns
,
renal insufficiency
,
pharmacovigilance
Elobixibat
non-alcoholic fatty liver disease
,
liver diseases
,
fatty liver
,
dyslipidemias
,
constipation
,
colonoscopy
Insulin
obesity
,
insulin resistance
,
abdominal obesity
Viaject
obesity
,
insulin resistance
,
abdominal obesity
Isoxaflutole
postoperative nausea and vomiting
,
vomiting
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use